See Why Alzamend Neuro Stock Is Rallying On Thursday

• Alzamend Neuro Inc (NASDAQ: ALZN) has received a written response to its meeting request regarding the FDA's Type B Pre‑Investigational New Drug (Pre-IND) application.

• Today's response provides a path for its planned clinical development of AL002, the Company says.

• AL002 uses a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

• The FDA agreed to Alzamend's proposed combined Phase 1/2 study.

• Alzamend will file the IND by the end of November and initiate the clinical trial of AL002 in Q1 of 2022.

• Related: Alzamend Recruits Altasciences To Conduct Early-Stage Trial Of Its Alzheimer's Candidate.

• Price Action: ALZN stock increased 33.5% at $3.04 during the market session on the last check Thursday.

See more from Benzinga

• Click here for options trades from Benzinga

• Investors Cheer AngioDynamics' Q1 Beat, Raised FY22 Sales Outlook

• Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.